Terns Pharmaceuticals announced the appointment of Scott Harris as chief development officer, or CDO, effective May 28 and the upcoming departure of Erin Quirk, president, head of research and development. Quirk will be transitioning her responsibilities and leaving the company to pursue other opportunities effective June 3. Harris will report to the CEO and oversee clinical operations, regulatory affairs, chemistry manufacturing and controls, quality assurance and project management.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals Announces Leadership Changes
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Reveals Encouraging TERN-701 Study Data
- Terns announces data from pharmacokinetic study of allosteric inhibitor
- Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation